Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer. (November 2022)

• Record Type: Journal Article
• Authors: Patil, Vijay; Kumar, Sravan; Noronha, Vanita; Menon, Nandini; Nawale, Kavita Prakash; Alone, Mitali; Waratkar, Gopichand; Dhumal, Sachin; Bhattacharjee, Atanu; Prabhash, Kumar
• Is Part Of: Oral oncology. Volume 134(2022)
• Publication Date: 2022-11
• Subjects: Cabazitaxel -- Docetaxel -- Head and neck cancer -- Palliative -- Long term -- Second Line; Mouth -- Cancer -- Periodicals; Mouth -- Tumors -- Periodicals; Mouth Diseases -- Periodicals; Mouth Neoplasms -- Periodicals; Bouche -- Cancer -- Périodiques; Bouche -- Tumeurs -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9943105
• DOI: 10.1016/j.oraloncology.2022.106085
• Languages: English
• ISSNs: 1368-8375

Abstract

Highlights: Cabazitaxel had inferior PFS in comparison to docetaxel. Cabazitaxel has inferior OS in comparison to docetaxel. Age and site of disease influence OS.